title: KP1019 (FFC14A) from bench to bedside: preclinical and early clinical development--an overview.
authors.affiliation: Institute of Inorganic Chemistry - Bioinorganic, Environmental and Radiochemistry, University of Vienna, Austria.
authors.forename: M A
authors.initials: MA
authors.lastname: Jakupec
authors.forename: V B
authors.initials: VB
authors.lastname: Arion
authors.forename: S
authors.initials: S
authors.lastname: Kapitza
authors.forename: E
authors.initials: E
authors.lastname: Reisner
authors.forename: A
authors.initials: A
authors.lastname: Eichinger
authors.forename: M
authors.initials: M
authors.lastname: Pongratz
authors.forename: B
authors.initials: B
authors.lastname: Marian
authors.forename: N
authors.initials: N
authors.lastname: Graf von Keyserlingk
authors.forename: B K
authors.initials: BK
authors.lastname: Keppler
mesh_terms: D000818:Animals; D000970:Antineoplastic Agents / Q000009:adverse effects / Q000493:pharmacokinetics / Q000494:pharmacology*; D017209:Apoptosis; D045744:Cell Line, Tumor; D017321:Clinical Trials, Phase I as Topic; D004353:Drug Evaluation, Preclinical; D006801:Humans; D007191:Indazoles / Q000009:adverse effects / Q000493:pharmacokinetics / Q000494:pharmacology*; D009942:Organometallic Compounds; D010084:Oxidation-Reduction; D017975:Ruthenium Compounds / Q000009:adverse effects / Q000493:pharmacokinetics / Q000494:pharmacology*; D014168:Transferrin / Q000378:metabolism
chemical_list: D000970:Antineoplastic Agents; D007191:Indazoles; D009942:Organometallic Compounds; D017975:Ruthenium Compounds; D014168:Transferrin; C499292:indazolium trans-(tetrachlorobis(1H-indazole)ruthenate (III))